Registry-listed formulations

Insulin, Isophane · chembl:CHEMBL2108964

Each study is counted once in the molecule profile. Registry products remain separate. Naming an ingredient does not establish that products are interchangeable or what participants received.

19 source entries across 19 studies. This list may not include all unresolved or historical entries.

  • NPH insulinRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • NPH insulinRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • NPH insulinRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Neutral protamine hagedorn insulinRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • NPH insulinRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • NPH insulinRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • NPH insulinRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • nph insulinRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • NPH InsulinRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • NPH insulinRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • NPH insulinRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • NPH insulinRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • NPH insulinRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • NPH insulinRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • NPH insulinRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Neutral protamine hagedorn insulinRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • NPH InsulinRegistry intervention

    Molecular identity unconfirmed

    View study and source
  • NPH insulinRegistry intervention

    Linked study entry; product equivalence not established

    View study and source
  • Intradermal injection of NPH insulinRegistry intervention

    Linked study entry; product equivalence not established

    View study and source

Success Metrics

Completion Rate
88%(15/17)
Active Trials
0(0%)
Results Posted
40%(6 trials)
Terminated
2(10%)

Phase Distribution

Phase 4
12
60%
Phase 2/3
1
5%
Phase 1
1
5%
Not Applicable
1
5%
Phase 3
4
20%

Phase Distribution

1

Early Stage

1

Mid Stage

16

Late Stage

Phase Distribution19 total trials
Phase 1Safety & dosage
1(5.3%)
Phase 2/3Combined phases
1(5.3%)
Phase 3Large-scale testing
4(21.1%)
Phase 4Post-market surveillance
12(63.2%)
N/ANon-phased studies
1(5.3%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

88.2%

15 of 17 finished

Non-Completion Rate

11.8%

2 ended early

Currently Active

0

trials recruiting

Total Trials

20

all time

Status Distribution
Completed(15)
Terminated(2)
Other(3)

Detailed Status

Completed15
unknown3
Terminated2

Development Timeline

Analytics

Development Status

Total Trials
20
Active
0
Success Rate
0.0%
Most Advanced
Phase 4

Trials by Phase

Phase 11 (5.3%)
Phase 2/31 (5.3%)
Phase 34 (21.1%)
Phase 412 (63.2%)
N/A1 (5.3%)

Trials by Status

unknown315%
terminated210%
completed1575%

Recent Activity

0 active trials
Showing 5 of 20
completednot_applicable

Comparative Analysis of Intralesional Platelet-Rich Plasma, NPH Insulin, and Vitamin C- A New Horizon and Future Hope for Linear Atrophic Scar Management

NCT07901283
terminatedphase_4

Comparison of Insulin Therapy in Treating Post-Transplant Diabetes

NCT01963728
completedphase_1

A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus

NCT02910518
completedphase_4

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin

NCT02967211
completedphase_4

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating Insulin

NCT02967224
View all 20 trials

Clinical Trials (20)

Showing 20 of 20 trials
NCT07901283Not Applicable

Comparative Analysis of Intralesional Platelet-Rich Plasma, NPH Insulin, and Vitamin C- A New Horizon and Future Hope for Linear Atrophic Scar Management

Completed
NCT01963728Phase 4

Comparison of Insulin Therapy in Treating Post-Transplant Diabetes

Terminated
NCT02910518Phase 1

A Study to Demonstrate Bioequivalence Between Insulin Glulisine U300 and Insulin Glulisine U100 After a Single Subcutaneous Dose Using the Euglycemic Clamp Technique, in Patients With Type 1 Diabetes Mellitus

Completed
NCT02967211Phase 4

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulin in Patients Already Using Basal Insulin

Completed
NCT02967224Phase 4

A "Real World" Trial to Determine Efficacy and Health Outcomes of Toujeo Compared to "Standard of Care" Basal Insulins in Insulin Naïve Patients Initiating Insulin

Completed
NCT03350984Phase 4

Insulin Schemes for Type 2 Diabetes Control

Completed
NCT03389490Phase 4

Toujeo Versus NPH Self-titration Study

Completed
NCT04664764Phase 4

Intermediate and Long Acting Insulin Young Children Type 1 Diabetes.

Unknown
NCT03511521Phase 4

Use of NPH Versus Basal Bolus Insulin for Steroid Induced Hyperglycemia

Terminated
NCT02451917Phase 4

Glargine Versus NPH in Patients With Chronic Kidney Disease

Completed
NCT03220425Phase 3

Evaluation of the Efficacy and Safety of Insulin Detemir Compared With That of NPH Insulin in Subjects With Type 1 Diabetes.

Completed
NCT00474045Phase 3

Efficacy and Safety of Insulin Detemir Versus Neutral Protamine Hagedorn (NPH) Insulin in Pregnant Women With Type 1 Diabetes

Completed
NCT01810952Phase 4

The Management of Glucocorticoid-Induced Hyperglycemia in Hospitalized Patients

Completed
NCT00115570Phase 3

Comparison of the Ability of Glulisine With Lispro to Control Type 1 Diabetes Mellitus in Children and Adolescents

Completed
NCT01223131Phase 3

Efficacy and Safety of Insulin Glargine Versus. Neutral Protamine Hagedorn (NPH) Insulin in Children With Type 1 Diabetes Above 6 Years Old.

Completed
NCT01500850Phase 4

Establishing Cardiovascular Biomarkers to Define Preferred Lantus® Use

Unknown
NCT01271517Phase 4

Basal Analog Study - Comparison of Lantus or Levemir With NPH Insulin From T1DM Diagnosis

Unknown
NCT00941148Phase 4

Beta-Cell Function of Insulin Glargine Compared to Neutral Protamine Hagedorn (NPH) Insuline and to Insulin Detemir in Combination With Metformin

Completed
NCT00490854Phase 2/3

A Study for Patients With Type 2 Diabetes Mellitus

Completed
NCT00468364

Comparison of Insulin Glargine and NPH Insulin at Night and at Hypoglycemia in Type 2 Diabetes

Completed

All 20 trials loaded

Drug Details

Intervention Type
Drug
Molecule Type
Protein
Total Trials
20

External References

ChEMBL
CHEMBL2108964